Heqet Therapeutics

Executive Summary

Heqet Therapeutics is a preclinical-stage biotechnology company pioneering first-in-class non-coding RNA-based therapies for cardiovascular diseases, with a primary focus on acute myocardial infarction (heart attack). Founded in 2021 and headquartered in Milan, Italy, the company leverages a disruptive approach targeting the underlying molecular mechanisms of cardiac damage and repair. Unlike traditional protein-coding gene therapies, Heqet's non-coding RNA compounds are designed to modulate gene expression with high specificity and low immunogenicity, potentially offering a novel therapeutic avenue for patients with limited treatment options. The company's platform addresses the urgent need for disease-modifying therapies that can prevent heart failure progression post-infarction, a leading cause of morbidity and mortality worldwide.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data in Acute MI Models40% success
• H1 2027Series A Financing Round55% success
• Q2 2027IND-Enabling Studies Initiation35% success